白蛋白结合型紫杉醇联合PD-1抑制剂治疗非小细胞肺癌的效果研究

Effectiveness Studies of Albumin-Bound Paclitaxel with PD-1 Inhibitors on the Treatment of Non-Small Cell Lung Cancer

目的研究白蛋白结合型紫杉醇联合程序性死亡蛋白-1(PD-1)抑制剂治疗非小细胞肺癌(NSCLC)的效果。方法回顾性分析焦作市第二人民医院2019年1月至2022年7月收治的76例NSCLC患者进行研究,根据临床治疗差异进行分组,其中白蛋白结合型紫杉醇对单一用药患者为对照组(N=38),白蛋白结合型紫杉醇联合PD-1抑制剂患者为研究组(N=38)。观察两组一定疗程治疗后临床疗效、细胞免疫指标、肿瘤标记物含量、血清炎性因子、不良反应。结果研究组治疗有效率(73.68%)与对照组(60.53%)比较,差异有统计学意义(P<0.05)。用药前,两组细胞免疫指标差异无统计学意义(P>0.05);用药后,研究组CD3^(+)、CD4^(+)均高于对照组,CD8^(+)低于对照组,差异有统计学意义(P<0.05)。用药前,两组肿瘤标记物含量差异无统计学意义(P>0.05);用药后,研究组肿瘤标记物含量均低于对照组,差异有统计学意义(P<0.05)。用药前,两组血清炎性因子水平差异无统计学意义(P>0.05);用药后,两组炎性因子水平均出现下降,且研究组水平低于对照组,差异有统计学意义(P<0.05)。两组不良反应情况差异无统计学意义(P>0.05)。结论白蛋白结合型紫杉醇联合PD-1抑制剂对非小细胞肺癌患者治疗效果理想,患者整体免疫水平好转,自身血清炎性因子明显下降,各项肿瘤标记物含量降低,整体效果理想,且安全性较高,值得应用。

Objective To study the clinical effectiveness of albumin-bound paclitaxel with programmed death-1(PD-1)inhibitors on the treatment of non-small cell lung cancer(NSCLC).Methods A total of 76 NSCLC patients treated from January 2019 to July 2022 in Jiaozuo Second People’s Hospital were reviewed.According to different treatment modes,38 cases of taking the albumin-bound paclitaxel were included in the control group;38 cases of taking the albumin-bound paclitaxel and PD-1 inhibitors were included in the research group.Clinical effects,cellular immunity indicators,tumor markers,serum inflammatory factors and adverse reactions were compared between two groups.Results The total effective rate of the study group was 73.68%,which was significantly higher than that of the control group(60.53%),with significant difference(P<0.05).There were no differences in cellular immune indexes between the two groups before treatment(P>0.05);After treatment,CD3^(+)and CD4^(+)in the study group were higher than those in the control group,and CD8^(+)was lower than that in the control group,with significant differences between the groups(P<0.05).There were no differences in the content of tumor markers between the two groups before treatment(P>0.05);After treatment,the content of tumor markers in the study group were lower than those in the control group,with significant differences between the groups(P<0.05).There were no differences in the level of serum inflammatory factors between the two groups before treatment(P>0.05),but the level of inflammatory factors in the two groups decreased after treatment,and the level in the study group were lower than those in the control group,with significant differences between the groups(P<0.05).There was no difference in adverse reactions between the two groups(P>0.05).Conclusion Albumin-bound paclitaxel combined with PD-1 inhibitor has an ideal treatment effect in patients with non-small cell lung cancer,the overall immune level is improved,the patient's serum inflammatory factors are significantly decreased,the content of various tumor markers are reduced,the overall effect is ideal,and the safety is high,it is worthy of application.